Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. - Test2 - elhamkhani - TriplyDB

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.

http://www.wikidata.org/entity/Q37169959

about

Precision targeted therapy of ovarian cancer Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer An update on PARP inhibitors for the treatment of cancer "Neurological complications of new chemotherapy agents".

P2860

Q28078658-7BC68D82-ECA9-4816-A490-84FA31090226 Q33704050-00EBA28D-C11D-4659-99C6-621C3D571D2D Q35142718-6314971C-6586-49A4-A2EC-C1B08BC0DF97 Q45069581-FB4CB7EA-AFD4-4C89-9F2C-07A82C8C0C0D

P2860

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.

http://www.wikidata.org/entity/Q37169959

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.

@en

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.

@nl

type

label

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.

@en

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.

@nl

prefLabel

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.

@en

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.

@nl

P1433

Q37169959-133D3703-A6B2-4C60-86E4-D1793A33748A

P1476

Q37169959-76F02F4C-F336-41E6-9F9B-A84C90EFCD37

P2093

Q37169959-3FA7710E-817C-4C5A-8F6E-96FB18BA1FA7

Q37169959-74A56AF1-8AE5-4C14-8429-173F7E195C14

P2860

Q37169959-01380DC8-293D-4F78-A934-B259741D5243

Q37169959-026A88AA-6E9E-4C4E-AEAA-5C5F3EBB2E32

Q37169959-04A5E1A6-2E1E-4785-9A93-71C37DC9B4CA

Q37169959-0C46C233-4D26-4C21-B9C1-F008E5210867

Q37169959-1580CC76-A1BE-45F8-BD90-CA888BF3AB90

Q37169959-15BFBB37-1150-4390-8131-069556D9D9A4

Q37169959-17475A6D-DBF2-4DDA-93C2-920C1309CEDA

Q37169959-1A7AA563-DD6A-46C3-8141-9FBA2E65AFEF

Q37169959-2CBB189F-7967-46F6-B83D-859881530547

Q37169959-414A5472-CB36-4F9C-AE7C-61C1503D5D2C

P304

Q37169959-5FF0ABF5-20AC-48BB-8EBD-2B75141428CC

P31

Q37169959-0A408787-BF8A-4F19-9CA2-E21AD4FAB1B2

P356

Q37169959-45E882BC-50EA-4F56-8032-A70003E7A10A

P407

Q37169959-A391C9D5-B8ED-4678-B4BD-0C2BBEE7CBF6

P478

Q37169959-9554265D-7CA9-479B-85F6-BEB47708EB9A

P577

Q37169959-2C4277F8-3B1F-420D-BF16-96B4E2C5D8F0

P5875

Q37169959-8D3BB88F-341F-46ED-82C2-C4111F7C384C

P698

Q37169959-261FC1FC-E61A-42EB-8F6C-E69057EBAA20

P921

Q37169959-DF658443-8B25-4ECE-BB7E-1BDA7E19B1B6

P932

Q37169959-BDBC3860-E212-4C9F-AEF7-C9B864AED2FF

P356

P1433

OncoTargets and Therapy

P1476

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.

@en

P2093

Heather M Shaw

http://www.w3.org/2001/XMLSchema#string

Marcia Hall

http://www.w3.org/2001/XMLSchema#string

P2860

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin

BRCAness: finding the Achilles heel in ovarian cancer

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Synthetic lethality--a new direction in cancer-drug development

P304

1197-1206

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S30748

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256666735

http://www.w3.org/2001/XMLSchema#string

P698

24043945

http://www.w3.org/2001/XMLSchema#string

P921

P932

3772750

http://www.w3.org/2001/XMLSchema#string